Matches in DBpedia 2014 for { <http://dbpedia.org/resource/Gemtuzumab_ozogamicin> ?p ?o. }
Showing items 1 to 60 of
60
with 100 items per page.
- Gemtuzumab_ozogamicin abstract "Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myelogenous leukemia from 2000-2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins. CD33 is expressed in most leukemic blast cells but also in normal hematopoietic cells, the intensity diminishing with maturation of stem cells. In the United States, it was approved under an accelerated-approval process by the FDA in 2000 for use in patients over the age of 60 with relapsed acute myelogenous leukemia (AML); or those who are not considered candidates for standard chemotherapy.Within the first year after approval, the FDA required a black box warning be added to Gemtuzumab packaging. The drug was noted to increase the risk of veno-occlusive disease in the absence of bone marrow transplantation. Later the onset of VOD was shown to occur at increased frequency in Gemtuzumab patients even following bone marrow transplantation. The drug was discussed in a 2008 JAMA article, which criticized the inadequacy of postmarketing surveillance of biologic agents.Common side effects of administration included shivering, fever, nausea and vomiting.Serious side effects included severe myelosuppression (suppressed activity of bone marrow, which is involved in formation of various blood cells [found in 98% of patients]), disorder of the respiratory system, tumor lysis syndrome, Type III hypersensitivity, venous occlusion, and death.".
- Gemtuzumab_ozogamicin atcPrefix "L01".
- Gemtuzumab_ozogamicin atcSuffix "XC05".
- Gemtuzumab_ozogamicin casNumber "220578-59-6".
- Gemtuzumab_ozogamicin drugbank "DB00056".
- Gemtuzumab_ozogamicin wikiPageID "2921579".
- Gemtuzumab_ozogamicin wikiPageRevisionID "563939478".
- Gemtuzumab_ozogamicin atcPrefix "L01".
- Gemtuzumab_ozogamicin atcSuffix "XC05".
- Gemtuzumab_ozogamicin casNumber "220578".
- Gemtuzumab_ozogamicin chembl "1201506".
- Gemtuzumab_ozogamicin chemspiderid "NA".
- Gemtuzumab_ozogamicin drugbank "DB00056".
- Gemtuzumab_ozogamicin hasPhotoCollection Gemtuzumab_ozogamicin.
- Gemtuzumab_ozogamicin kegg "D03259".
- Gemtuzumab_ozogamicin legalUs "Rx-only".
- Gemtuzumab_ozogamicin mabType "mab".
- Gemtuzumab_ozogamicin medlineplus "a607075".
- Gemtuzumab_ozogamicin molecularWeight "151".
- Gemtuzumab_ozogamicin pregnancyCategory "D".
- Gemtuzumab_ozogamicin routesOfAdministration Intravenous_therapy.
- Gemtuzumab_ozogamicin source "zu/o".
- Gemtuzumab_ozogamicin target CD33.
- Gemtuzumab_ozogamicin tradename "Mylotarg".
- Gemtuzumab_ozogamicin type "mab".
- Gemtuzumab_ozogamicin verifiedfields "changed".
- Gemtuzumab_ozogamicin verifiedrevid "476992617".
- Gemtuzumab_ozogamicin subject Category:Monoclonal_antibodies_for_tumors.
- Gemtuzumab_ozogamicin subject Category:Orphan_drugs.
- Gemtuzumab_ozogamicin subject Category:Withdrawn_drugs.
- Gemtuzumab_ozogamicin type Agent114778436.
- Gemtuzumab_ozogamicin type CausalAgent100007347.
- Gemtuzumab_ozogamicin type Drug103247620.
- Gemtuzumab_ozogamicin type Matter100020827.
- Gemtuzumab_ozogamicin type OrphanDrugs.
- Gemtuzumab_ozogamicin type PhysicalEntity100001930.
- Gemtuzumab_ozogamicin type Substance100020090.
- Gemtuzumab_ozogamicin type WithdrawnDrugs.
- Gemtuzumab_ozogamicin type Drug.
- Gemtuzumab_ozogamicin type DrugProduct.
- Gemtuzumab_ozogamicin type FunctionalSubstance.
- Gemtuzumab_ozogamicin comment "Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myelogenous leukemia from 2000-2010. It was withdrawn from market in June 2010 when a clinical trial showed the drug increased patient death and added no benefit over conventional cancer therapies.Gemtuzumab is a monoclonal antibody to CD33 linked to a cytotoxic agent from the class of calicheamicins.".
- Gemtuzumab_ozogamicin label "Gemtuzumab ozogamicin".
- Gemtuzumab_ozogamicin label "Gemtuzumab ozogamicin".
- Gemtuzumab_ozogamicin label "Gemtuzumab".
- Gemtuzumab_ozogamicin label "Gemtuzumab-Ozogamicin".
- Gemtuzumab_ozogamicin label "Gentuzumab ozogamicina".
- Gemtuzumab_ozogamicin label "جيمتوزوماب أوزوغاميسين".
- Gemtuzumab_ozogamicin sameAs Gemtuzumab-Ozogamicin.
- Gemtuzumab_ozogamicin sameAs Gemtuzumab_ozogamicin.
- Gemtuzumab_ozogamicin sameAs Gemtuzumab.
- Gemtuzumab_ozogamicin sameAs Gentuzumab_ozogamicina.
- Gemtuzumab_ozogamicin sameAs m.08cs96.
- Gemtuzumab_ozogamicin sameAs Q412685.
- Gemtuzumab_ozogamicin sameAs Q412685.
- Gemtuzumab_ozogamicin sameAs gemtuzumab_ozogamicin.
- Gemtuzumab_ozogamicin sameAs DB00056.
- Gemtuzumab_ozogamicin sameAs Gemtuzumab_ozogamicin.
- Gemtuzumab_ozogamicin wasDerivedFrom Gemtuzumab_ozogamicin?oldid=563939478.
- Gemtuzumab_ozogamicin isPrimaryTopicOf Gemtuzumab_ozogamicin.